Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2019

View Archived Issues

Novel pgm2 gene knockout mouse model of PGM1-CDG

APOE4 strongly affects microglial function

Jacobio recruiting patients with advanced solid tumors for phase I study of JAB-3312

Nitazoxanide amplifies RNA sensor and type I interferon activities and inhibits Ebola virus

Getting to the root of schizophrenia

First patient dosed in phase I study of KO-539 for AML

Precision BioSciences announces FDA clearance of IND for PBCAR-20-A

Preliminary clinical data presented from U.S. phase II study of ANAVEX 2-73 in Rett syndrome

Discovery of novel PS-targeting zinc dipicolylamine-based drug conjugates

YK-4-279 and TK-216 show promising preclinical activity in models of lymphoma

miR-744 found to be a prognostic factor in NSCLC

B cells, T cells honored as hybrids reported

Phase II data presented for selatogrel in patients with acute myocardial infarction

Stanford University patents GPAM inhibitors

Sumitomo Dainippon Pharma presents dopamine D1 and D2 receptor antagonists

DE Shaw Research and Relay Therapeutics describe new PTP-1D inhibitors

Newave Pharmaceutical identifies WEE1hu inhibitors

Boehringer Ingelheim synthesizes new EGFR mutant inhibitors

Edoxaban in atrial fibrillation patients after PCI: Results from ENTRUST-AF PCI

CARB-X to fund Procarta's development of new class of antibiotics targeting ESKAPE pathogens

Acceleron ends development of ACE-083 for facioscapulohumeral muscular dystrophy

DSMC recommends continuation of U.S. study of IDCT for degenerative disc disease

Phase III PREVENT trial of Cosentyx in nr-axSpA meets 16-week primary endpoint

Neuronascent studies NNI-362 in healthy aged volunteers in first-in-human trial

Life Molecular Imaging opens enrollment for phase II trial of next-generation tau PET tracer PI-2620

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...